Phase IIb IFNalpha Kinoid Study Reveals Positive Results for People with Systemic Lupus Erythematosus
As previously reported by Inside Lupus Research, IFNalpha Kinoid (IFN-K) has shown to block the pro-inflammatory molecule IFN-alpha that activates autoimmune response and is overproduced in people with lupus. Phase IIb assessed the efficacy and safety of IFN-K in patients with active systemic lupus erythematosus (SLE) on standard of care therapy through a randomized, double-blind, placebo-controlled (PBO), multi-center study.
Among those who completed the study, the vaccine was well-tolerated, steroid tapering and achieving Lupus Low Disease Activity State (LLDAS) favored participants treated with IFN-K, and serious adverse events (SAEs) were more common in the PBO group. These findings merit further evaluation in phase 3 studies. Continue to follow the Lupus Foundation of America for updates on IFNalpha Kinoid.